Editor's note: BioWorld has always kept a watchful eye on big pharma developments as they relate to the biotech space. Now we're making it easier for readers by separating pharma business and clinical news into these columns of brief news.

• Merck & Co. Inc., of Whitehouse Station, N.J., said it plans to file a new drug application for Suvorexant, its orexin receptor antagonist, in insomnia this year based on results from two pivotal Phase III trials.